Back to results
US 12,365,664 B2Granted
Small molecule inhibitors of SRC tyrosine kinase
AssigneesDana-Farber Cancer Institute, Inc., Board of Regents, The University of Texas System
InventorsNathanael S. Gray, Guangyan Du, Tinghu Zhang, Nathaniel Henning, Suman Rao, Kenneth Westover, Deepak Gurbani
Life of this patent
Estimating the term…
Abstract
Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof. Also disclosed herein are methods of using the compounds of Formula (I) in the treatment of certain diseases (e.g., cancer).
Claims24
A compound of Formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- E is an electrophile;
- L is a bond or alkylenyl;
- each R1 is independently selected from hydrogen and alkyl;
- R2 is selected from hydrogen and amino;
- R3 is selected from alkyl, —C(═O)NR1-alkyl, —C(═O)NR1-aryl, alkoxy, aryl, heteroaryl, cycloalkyl, halogen, and aralkyloxy;
- or R2 and R3, taken together with the carbon atoms to which they are attached, combine to form a heteroaryl;
- R4 is selected from hydrogen and alkyl;
- each R5 is independently selected from alkyl and halogen;
- m is 0 or 1;
- two of R11, R12, and R13 are independently hydrogen or alkyl;
- one of R11, R12, and R13 is selected from
- provided that if R1 is hydrogen, R2 is hydrogen, R3 is chloro, R4 is hydrogen, m is 0, E is
- L is a bond, Y is O, L3 is —NRL3a—, RL3a, RE1, RE2, and RE3 are hydrogen, R11 is hydrogen,
- and R12 is hydrogen, then R13 is not
12 more elements
A compound selected from:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.